Area of research
Hematology · Genetics
Research interest
Research interests include Acute Myeloid Leukemia Research, Chronic Myeloid Leukemia Treatments, Chronic Lymphocytic Leukemia Research, and Myeloproliferative Neoplasms: Diagnosis and Treatment.
Improved Inter-Lab Precision After CML International Scale Adoption: a 15-year history of BCR::ABL1 Proficiency Testing
Impact of Germline CHEK2 Pathogenic Variants on the Risk of Acute Myeloid Leukemia and Myelodysplastic Syndrome.
Table S5 from Impact of Germline CHEK2 Pathogenic Variants on the Risk of Acute Myeloid Leukemia and Myelodysplastic Syndrome
Figure S1 from Impact of Germline CHEK2 Pathogenic Variants on the Risk of Acute Myeloid Leukemia and Myelodysplastic Syndrome
Table S2 from Impact of Germline CHEK2 Pathogenic Variants on the Risk of Acute Myeloid Leukemia and Myelodysplastic Syndrome
Supplementary Data from Impact of Germline CHEK2 Pathogenic Variants on the Risk of Acute Myeloid Leukemia and Myelodysplastic Syndrome
Table S3 from Impact of Germline CHEK2 Pathogenic Variants on the Risk of Acute Myeloid Leukemia and Myelodysplastic Syndrome
Table S1 from Impact of Germline CHEK2 Pathogenic Variants on the Risk of Acute Myeloid Leukemia and Myelodysplastic Syndrome
Supplementary Methods_ Results from Impact of Germline CHEK2 Pathogenic Variants on the Risk of Acute Myeloid Leukemia and Myelodysplastic Syndrome
Table S4 from Impact of Germline CHEK2 Pathogenic Variants on the Risk of Acute Myeloid Leukemia and Myelodysplastic Syndrome
Data from Impact of Germline CHEK2 Pathogenic Variants on the Risk of Acute Myeloid Leukemia and Myelodysplastic Syndrome
The genomic basis of childhood T-lineage acute lymphoblastic leukaemia.
Overcoming clinical BCR-ABL1 compound mutant resistance with combined ponatinib and asciminib therapy
Evaluation of a New Closed-System Automated RT-qPCR Assay for the Rapid Detection and Monitoring of Common Nucleophosmin Mutations in Patients with Acute Myeloid Leukemia.
Comparison and validation of the 2022 European LeukemiaNet guidelines in acute myeloid leukemia.
NGS-defined measurable residual disease (MRD) after initial chemotherapy as a prognostic biomarker for acute myeloid leukemia.
Distinguishing STAT3/STAT5B-mutated large granular lymphocyte leukemia from myeloid neoplasms by genetic profiling.
Samples from patients with AML show high concordance in detection of mutations by NGS at local institutions vs central laboratories.
Supplementary Data from A Novel Germline Variant in CSF3R Reduces N-Glycosylation and Exerts Potent Oncogenic Effects in Leukemia
Data from A Novel Germline Variant in CSF3R Reduces N-Glycosylation and Exerts Potent Oncogenic Effects in Leukemia
Supplementary Data from A Novel Germline Variant in CSF3R Reduces N-Glycosylation and Exerts Potent Oncogenic Effects in Leukemia
Data from A Novel Germline Variant in CSF3R Reduces N-Glycosylation and Exerts Potent Oncogenic Effects in Leukemia
Identification and prioritization of myeloid malignancy germline variants in a large cohort of adult patients with AML.
Adult acute myeloid leukemia patients with <i>NUP98</i> rearrangement have frequent cryptic translocations and unfavorable outcome
Adult acute myeloid leukemia patients with <i>NUP98</i> rearrangement have frequent cryptic translocations and unfavorable outcome.
Distinguishing <i>STAT3/STAT5B</i>-mutated large granular lymphocyte leukemia from myeloid neoplasms by genetic profiling
Comprehensive molecular characterization of a rare case of Philadelphia chromosome-positive acute myeloid leukemia.
NGS-defined measurable residual disease (MRD) after initial chemotherapy as a prognostic biomarker for acute myeloid leukemia
Identification and prioritization of myeloid malignancy germline variants in a large cohort of adult patients with AML
A novel activating JAK1 mutation in chronic eosinophilic leukemia.